X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1287) 1287
Publication (145) 145
Book Review (39) 39
Book Chapter (15) 15
Conference Proceeding (8) 8
Magazine Article (5) 5
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (936) 936
index medicus (570) 570
catechol-o-methyltransferase (548) 548
male (461) 461
animals (441) 441
female (414) 414
pharmacology & pharmacy (406) 406
catechol o-methyltransferase inhibitors (386) 386
parkinson disease - drug therapy (367) 367
neurosciences (310) 310
antiparkinson agents - therapeutic use (283) 283
parkinson's disease (265) 265
clinical neurology (259) 259
levodopa (235) 235
middle aged (231) 231
levodopa - therapeutic use (229) 229
catechol o-methyltransferase - genetics (219) 219
catechol o-methyltransferase - metabolism (216) 216
psychiatry (204) 204
adult (191) 191
dopamine (189) 189
aged (174) 174
entacapone (174) 174
tolcapone (171) 171
rats (161) 161
catechols - therapeutic use (147) 147
parkinsons-disease (141) 141
double-blind (140) 140
enzyme inhibitors - therapeutic use (137) 137
pharmacokinetics (132) 132
comt (130) 130
l-dopa (115) 115
motor fluctuations (115) 115
metabolism (113) 113
nitriles (113) 113
pharmacogenetics (111) 111
drug therapy, combination (110) 110
dopamine - metabolism (108) 108
genotype (105) 105
antiparkinson agents - adverse effects (104) 104
treatment outcome (100) 100
analysis (98) 98
research (97) 97
double-blind method (96) 96
mice (94) 94
benzophenones - therapeutic use (93) 93
brain (93) 93
nitrophenols (93) 93
article (92) 92
schizophrenia (91) 91
dose-response relationship, drug (90) 90
genetic aspects (90) 90
catechol o-methyltransferase (88) 88
polymorphism (88) 88
catechols - pharmacology (86) 86
dopamine agonists - therapeutic use (85) 85
levodopa - adverse effects (84) 84
enzyme inhibitors - pharmacology (83) 83
physiological aspects (83) 83
methylation (82) 82
levodopa - pharmacokinetics (81) 81
biochemistry & molecular biology (78) 78
levodopa - administration & dosage (76) 76
toxicology (76) 76
antiparkinson agents - administration & dosage (73) 73
enzymes (71) 71
monoamine oxidase inhibitors - therapeutic use (71) 71
neurology (70) 70
dopa (69) 69
polymorphism, genetic (69) 69
benzophenones - pharmacology (68) 68
time factors (68) 68
antiparkinson agents - pharmacology (67) 67
drug therapy (67) 67
antiparkinson agents - pharmacokinetics (66) 66
catechin (66) 66
catechol (64) 64
parkinson disease - physiopathology (64) 64
genetics (62) 62
prefrontal cortex (62) 62
genes (61) 61
inhibition (61) 61
metabolites (61) 61
risk factors (60) 60
care and treatment (59) 59
health aspects (59) 59
kinetics (59) 59
young adult (59) 59
polymorphism, single nucleotide (58) 58
association (57) 57
carbidopa - therapeutic use (57) 57
parkinsons disease (57) 57
pharmacology (57) 57
brain - metabolism (55) 55
comt inhibitor (55) 55
comt inhibitors (55) 55
mental disorders (54) 54
parkinson disease - metabolism (54) 54
drug interactions (53) 53
levodopa - pharmacology (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1252) 1252
German (15) 15
Spanish (7) 7
Russian (6) 6
Japanese (5) 5
French (4) 4
Finnish (2) 2
Chinese (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Movement Disorders, ISSN 0885-3185, 05/2017, Volume 32, Issue 5, pp. 739 - 749
ABSTRACT Background There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of gut microbiota could explain several... 
confounding | Parkinson's disease | gut microbiome | functional pathways | medications | COMMUNITIES | CLINICAL NEUROLOGY | TAXONOMY | RIBOSOMAL-RNA SEQUENCES | MICROGLIA | CHAIN FATTY-ACIDS | SODIUM-BUTYRATE | ASSIGNMENT | DIVERSITY | ASSOCIATION | MANIFESTATIONS | United States - epidemiology | Vegetables | Age Factors | Humans | Lactobacillaceae - genetics | Male | Parkinson Disease - drug therapy | Dysbiosis - microbiology | Case-Control Studies | Antiparkinson Agents - therapeutic use | Carbidopa - therapeutic use | Parkinson Disease - epidemiology | Female | Verrucomicrobia - genetics | Cholinergic Antagonists - therapeutic use | Fruit | Pasteurellaceae - genetics | Levodopa - therapeutic use | Bifidobacterium - genetics | Risk Factors | Catechol O-Methyltransferase Inhibitors - therapeutic use | Gastrointestinal Microbiome - genetics | Confounding Factors (Epidemiology) | Parkinson Disease - microbiology | Diet | Dysbiosis - epidemiology | Sex Factors | RNA, Ribosomal, 16S - genetics | Drug Combinations | Physiological aspects | Microbiota (Symbiotic organisms) | RNA | Xenobiotics | Analysis | Antiparkinsonian agents | Dysbacteriosis | rRNA 16S | Demography | Neurodegenerative diseases | Digestive system | Methyltransferase | Parkinsons disease | Abundance | Catechol | Catechol O-methyltransferase | Plants | Levodopa | Digestive tract | Movement disorders | Deoxyribonucleic acid--DNA | DNA sequencing
Journal Article
Journal Article
Journal of Neural Transmission, ISSN 0300-9564, 11/2014, Volume 121, Issue 11, pp. 1357 - 1366
Journal Article
Journal of Neuroimmunology, ISSN 0165-5728, 2014, Volume 276, Issue 1, pp. 135 - 141
Abstract Reduced levels of noradrenaline (NA) in CNS of multiple sclerosis patients could be due to metabolism by catechol- O -methyltransferase (COMT). In... 
Neurology | Allergy and Immunology | Experimental autoimmune encephalomyelitis | Multiple sclerosis | Catecholamine | COMT | Noradrenaline | MONOAMINE-OXIDASE | ADRENERGIC-RECEPTOR DENSITY | MULTIPLE-SCLEROSIS PATIENTS | ALZHEIMERS-DISEASE | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | MONONUCLEAR-CELLS | SPINAL-CORD | IMMUNOLOGY | NEUROSCIENCES | FUNCTIONAL OUTCOMES | LOCUS-COERULEUS | PARKINSONS-DISEASE | Freund's Adjuvant - toxicity | Spinal Cord - drug effects | Spinal Cord - metabolism | Nitriles - pharmacology | Peptide Fragments - toxicity | Humans | Middle Aged | Male | Catechol O-Methyltransferase - genetics | Catechol O-Methyltransferase - metabolism | Myelin-Oligodendrocyte Glycoprotein - toxicity | Encephalomyelitis, Autoimmune, Experimental - chemically induced | T-Lymphocytes - metabolism | Time Factors | Catechols - therapeutic use | Spinal Cord - pathology | T-Lymphocytes - drug effects | Aged, 80 and over | Blood-Brain Barrier - physiology | Catechols - pharmacology | Female | Disease Models, Animal | Encephalomyelitis, Autoimmune, Experimental - pathology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Catechol O-Methyltransferase Inhibitors - therapeutic use | Blood-Brain Barrier - drug effects | Multiple Sclerosis - complications | Animals | Multiple Sclerosis - pathology | Aged | Mice | Nitriles - therapeutic use | Catechin | Transferases | Myelin proteins
Journal Article
Journal of Food Science, ISSN 0022-1147, 09/2018, Volume 83, Issue 9, pp. 2369 - 2374
The risk for breast and colon cancer may be lowered in part by high intake of fruits and vegetables. Fruits such as grapes are abundant in bioactive compounds... 
cancer | catechol‐O‐methyltransferase | anthocyanins | nitrocatechols | grapes | catechol-O-methyltransferase | RICH EXTRACT | FOOD SCIENCE & TECHNOLOGY | PROLIFERATION | FLAVONOIDS | COLON-CANCER | TEA | IN-VITRO | GUT MICROFLORA | METABOLISM | ANTIOXIDANT | Cell Proliferation | Vitis - chemistry | Nitriles - pharmacology | Oxidative Stress | Plant Extracts - pharmacology | Catechol O-Methyltransferase Inhibitors - pharmacology | Colonic Neoplasms - drug therapy | Humans | Tetrazolium Salts | Catechol O-Methyltransferase - metabolism | Plant Extracts - metabolism | Catechols - therapeutic use | Thiazoles | Catechols - pharmacology | Anthocyanins - therapeutic use | Female | Glucosides - therapeutic use | Antineoplastic Agents, Phytogenic - metabolism | Phytotherapy | Antineoplastic Agents, Phytogenic - therapeutic use | Caco-2 Cells | Anthocyanins - pharmacology | Glucosides - pharmacology | Fruit - chemistry | Catechol O-Methyltransferase Inhibitors - therapeutic use | Anthocyanins - metabolism | Breast Neoplasms - drug therapy | Glucosides - metabolism | Drug Synergism | HT29 Cells | Antineoplastic Agents, Phytogenic - pharmacology | Methylation | Plant Extracts - therapeutic use | Nitriles - therapeutic use | Anthocyanin | Care and treatment | Grapes | Oncology, Experimental | Cancer cells | Entacapone | Research | Properties | Health aspects | Cancer | Cell culture | Biotechnology | Oxidative stress | Transformation | Media (culture) | Liver | Methyltransferase | Catechol O-methyltransferase | Fruits | Anticancer properties | Colon cancer | Bioactive compounds | Polyphenols | Inhibition | Colon | Health risks | Catechol | Breast cancer | Bioavailability | Tumor cell lines | Metabolism | Organic chemistry | Cell lines | Culture media | Anthocyanins | Antitumor activity | Viability
Journal Article
Journal Article
Journal Article
Journal Article